Akebia Therapeutics, Inc.

AKBA

Explore Our Financial Data > Companies > Akebia Therapeutics, Inc.
{{popupValue}}
{{popupSubtitle}}
Documentation
Excel
API
Download

Identification

Click on a field for details on how to access that data via Web API, Excel, or CSV Download.

Ticker
AKBA
CIK0001517022
SIC2834
SectorManufacturing
Industry CategoryPharmaceutical Products
Industry GroupPharmaceutical Preparations

Contact

Address245 FIRST STREET, CAMBRIDGE, MA, 02142
Website akebia.com
Phone617-871-2098
CEOJohn P. Butler
Employees430

Access This Data

Our team will help you customize a package that meets the needs of your business.

Request a Consultation

Standardized Financials

docs

Intrinio provides professional-grade historical financial data. This data is standardized, cleansed and verified to ensure the highest quality data sourced directly from the XBRL financial statements. The primary purpose of standardized financials are to facilitate comparability across a single company’s fundamentals and across all companies fundamentals.

For example, it is possible to compare total revenues between two companies as of a certain point in time, or within a single company across multiple time periods. This is not possible using the as reported financial statements because of the inherent complexity of reporting standards.

Below is a preview of several data points from each financial statement, as well as a sample of our many calculated metrics:

Income Statement
Revenue$184.91 million
Pre-Tax Income$-45.31 million
Net Income$-45.31 million
Net Income to Common$-45.31 million
EPS$-0.21
View All
Balance Sheet
Cash$113.37 million
Assets$310.18 million
Liabilities$285.60 million
Common Equity$24.58 million
Liabilities & Equity$310.18 million
View All
Cash Flow Statement
Net Income$-45.31 million
Cash From Operating Activities$-34.81 million
Cash From Investing Activities$121,000.00
Cash From Financing Activities$106.13 million
Change in Cash$71.44 million
View All
Calculations
NOPAT$-15.42 million
EBITDA$10.78 million
Price to EarningsN/A
Price to Book$39.75
ROE3385.36%
View All

Latest News

docs

Intrinio provides up-to-date news articles on every US company from various sources. Here are several examples:

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights

Akebia to Host Conference Call on August 7, 2025, at 8:00 a.m. EDTCAMBRIDGE, Mass., July 31, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA) today announced plans to release its financial results for the second quarter ended June 30, 2025, on Thursday, August 7, 2025, prior to the open of financial markets. Akebia will host a conference call on Thursday, August 7, 2025, at 8:00 a.m. EDT to discuss its financial results and recent business highlights. To access the call, please

Article Link

H.C. Wainwright Rates Akebia Therapeutics (AKBA) Stock Buy

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the 10 Best Performing Penny Stocks So Far in 2025. On June 4, H.C. Wainwright analysts initiated coverage of Akebia Therapeutics, Inc. (NASDAQ:AKBA) and gave it a “Buy” rating with a price target of $8. This decision was based on confidence in the company’s drug, Vafseo (vadadustat), which […]

Article Link

Akebia Therapeutics (AKBA) Kidney Therapy Vafseo Gaining Market Share

Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best high-return penny stocks to buy now. On July 14, 2025, Akebia shared key updates during the H.C. Wainwright Kidney Conference, emphasizing the rollout of its oral anemia treatment Vafseo, prescribed by over 640 physicians in Q1. With initial pricing at $15,500 annually and post-TDAPA rates expected […]

Article Link

Akebia Therapeutics (AKBA) Upgraded to Strong Buy: Here's What You Should Know

Akebia Therapeutics (AKBA) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Article Link

Is Akebia Therapeutics (AKBA) Stock Outpacing Its Medical Peers This Year?

Here is how Akebia Therapeutics (AKBA) and ResMed (RMD) have performed compared to their sector so far this year.

Article Link